Circulating miR-148b and miR-133a as biomarkers for breast cancer detection

Oncotarget

Volumn 5, Issue 14, 2014, Pages 5284-5294

  Shen, Jie ^a   Hu, Qiang ^b,c   Schrauder, Michael ^d   Yan, Li ^b   Wang, Dan ^b   Medico, Leonardo ^b   Guo, Yuqing ^b   Yao, Song ^b   Zhu, Qianqian ^b   Liu, Biao ^b   Qin, Maochun ^b   Beckmann, Matthias W ^d   Fasching, Peter A ^d   Strick, Reiner ^d   Johnson, Candace S ^b   Ambrosone, Christine B ^b   Zhao, Hua ^a   Liu, Song ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^d UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Biomarkers; Breast cancer; Circulating microRNAs; Detection

Indexed keywords

MICRORNA; MICRORNA 107; MICRORNA 127 3P; MICRORNA 130A; MICRORNA 133A; MICRORNA 136; MICRORNA 139 5P; MICRORNA 142 5P; MICRORNA 148B; MICRORNA 151 5P; MICRORNA 1974; MICRORNA 199A 3P; MICRORNA 199A 5P; MICRORNA 22; MICRORNA 221; MICRORNA 28 5P; MICRORNA 326; MICRORNA 335; MICRORNA 339 5P; MICRORNA 33A; MICRORNA 382; MICRORNA 409 3P; MICRORNA 423 3P; MICRORNA 485 3P; MICRORNA 495; MICRORNA 543; MICRORNA 766; MICRORNA 99B; TUMOR MARKER; UNCLASSIFIED DRUG; MIRN133 MICRORNA, HUMAN; MIRN148 MICRORNA, HUMAN;

ADULT; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER DIAGNOSIS; CANCER SCREENING; CAUCASIAN; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; INTRADUCTAL CARCINOMA; MAJOR CLINICAL STUDY; POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; RNA ANALYSIS; TUMOR VOLUME; UPREGULATION; VALIDATION STUDY; BLOOD; BREAST TUMOR; CASE CONTROL STUDY; GENETICS; MCF 7 CELL LINE; PATHOLOGY; TUMOR CELL LINE;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; FEMALE; HUMANS; MCF-7 CELLS; MICRORNAS;

EID: 84906246668     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2014     Document Type: Article

References (66)

1. Wu W, Sun M, Zou GM and Chen J. MicroRNA and cancer: Current status and prospective. International journal of cancer Journal international du cancer. 2007; 120(5):953-960.
2. Wang Y, Stricker HM, Gou D and Liu L. MicroRNA: past and present. Frontiers in bioscience: a journal and virtual library. 2007; 12:2316-2329.
3. Chen PY and Meister G. microRNA-guided posttranscriptional gene regulation. Biological chemistry. 2005; 386(12):1205-1218.
4. Alvarez-Garcia I and Miska EA. MicroRNA functions in animal development and human disease. Development. 2005; 132(21):4653-4662.
5. Gregory RI and Shiekhattar R. MicroRNA biogenesis and cancer. Cancer research. 2005; 65(9):3509-3512.
6. Lehmann U. Aberrant DNA methylation of microRNA genes in human breast cancer-a critical appraisal. Cell and tissue research. 2014.
7. Xiao YF, Yong X, Fan YH, Lu MH, Yang SM and Hu CJ. microRNA detection in feces, sputum, pleural effusion and urine: novel tools for cancer screening (Review). Oncology reports. 2013; 30(2):535-544.
8. de Planell-Saguer M and Rodicio MC. Analytical aspects of microRNA in diagnostics: a review. Analytica chimica acta. 2011; 699(2):134-152.
9. Andorfer CA, Necela BM, Thompson EA and Perez EA. MicroRNA signatures: clinical biomarkers for the diagnosis and treatment of breast cancer. Trends in molecular medicine. 2011; 17(6):313-319.
10. Zoon CK, Starker EQ, Wilson AM, Emmert-Buck MR, Libutti SK and Tangrea MA. Current molecular diagnostics of breast cancer and the potential incorporation of microRNA. Expert review of molecular diagnostics. 2009; 9(5):455-467.
11. Deng S, Calin GA, Croce CM, Coukos G and Zhang L. Mechanisms of microRNA deregulation in human cancer. Cell cycle. 2008; 7(17):2643-2646.
12. Zhang L, Yang N and Coukos G. MicroRNA in human cancer: one step forward in diagnosis and treatment. Advances in experimental medicine and biology. 2008; 622:69-78.
13. Kosaka N, Iguchi H and Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer science. 2010; 101(10):2087-2092.
14. Wang J, Zhang KY, Liu SM and Sen S. Tumor-Associated Circulating MicroRNAs as Biomarkers of Cancer. Molecules. 2014; 19(2):1912-1938.
15. Farina NH, Wood ME, Perrapato SD, Francklyn CS, Stein GS, Stein JL and Lian JB. Standardizing Analysis of Circulating MicroRNA: Clinical and Biological Relevance. Journal of cellular biochemistry. 2013.
16. Schwarzenbach H. Circulating nucleic acids as biomarkers in breast cancer. Breast cancer research: BCR. 2013; 15(5):211.
17. Ma R, Jiang T and Kang X. Circulating microRNAs in cancer: origin, function and application. Journal of experimental & clinical cancer research: CR. 2012; 31:38.
18. Yu DC, Li QG, Ding XW and Ding YT. Circulating MicroRNAs: Potential Biomarkers for Cancer. International journal of molecular sciences. 2011; 12(3):2055-2063.
19. Mostert B, Sieuwerts AM, Martens JW and Sleijfer S. Diagnostic applications of cell-free and circulating tumor cell-associated miRNAs in cancer patients. Expert review of molecular diagnostics. 2011; 11(3):259-275.
20. Heneghan HM, Miller N, Kelly R, Newell J and Kerin MJ. Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. The oncologist. 2010; 15(7):673-682.
21. Vlassov VV, Laktionov PP and Rykova EY. Circulating nucleic acids as a potential source for cancer biomarkers. Current molecular medicine. 2010; 10(2):142-165.
22. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J and Kerin MJ. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Annals of surgery. 2010; 251(3):499-505.
23. Zhu W, Qin W, Atasoy U and Sauter ER. Circulating microRNAs in breast cancer and healthy subjects. BMC research notes. 2009; 2:89.
24. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America. 2008; 105(30):10513-10518.
25. Zhao H, Shen J, Medico L, Wang D, Ambrosone CB and Liu S. A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PloS one. 2010; 5(10):e13735.
26. Blanchard K, Colbert JA, Kopans DB, Moore R, Halpern EF, Hughes KS, Smith BL, Tanabe KK and Michaelson JS. Long-term risk of false-positive screening results and subsequent biopsy as a function of mammography use. Radiology. 2006; 240(2):335-342.
27. Waters PS, McDermott AM, Wall D, Heneghan HM, Miller N, Newell J, Kerin MJ and Dwyer RM. Relationship between circulating and tissue microRNAs in a murine model of breast cancer. PloS one. 2012; 7(11):e50459.
28. Healy NA, Heneghan HM, Miller N, Osborne CK, Schiff R and Kerin MJ. Systemic mirnas as potential biomarkers for malignancy. International journal of cancer Journal international du cancer. 2012; 131(10):2215-2222.
29. Wu X, Somlo G, Yu Y, Palomares MR, Li AX, Zhou W, Chow A, Yen Y, Rossi JJ, Gao H, Wang J, Yuan YC, Frankel P, Li S, Ashing-Giwa KT, Sun G, et al. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. Journal of translational medicine. 2012; 10:42.
30. Kumar S, Keerthana R, Pazhanimuthu A and Perumal P. Overexpression of circulating miRNA-21 and miRNA-146a in plasma samples of breast cancer patients. Indian journal of biochemistry & biophysics. 2013; 50(3):210-214.
31. Eichelser C, Flesch-Janys D, Chang-Claude J, Pantel K and Schwarzenbach H. Deregulated serum concentrations of circulating cell-free microRNAs miR-17, miR-34a, miR-155, and miR-373 in human breast cancer development and progression. Clinical chemistry. 2013; 59(10):1489-1496.
32. Leidner RS, Li L and Thompson CL. Dampening enthusiasm for circulating microRNA in breast cancer. PloS one. 2013; 8(3):e57841.
33. Zeng RC, Zhang W, Yan XQ, Ye ZQ, Chen ED, Huang DP, Zhang XH and Huang GL. Down-regulation of miRNA-30a in human plasma is a novel marker for breast cancer. Medical oncology. 2013; 30(1):477.
34. Mar-Aguilar F, Mendoza-Ramirez JA, Malagon-Santiago I, Espino-Silva PK, Santuario-Facio SK, Ruiz-Flores P, Rodriguez-Padilla C and Resendez-Perez D. Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Disease markers. 2013; 34(3):163-169.
35. Ng EK, Li R, Shin VY, Jin HC, Leung CP, Ma ES, Pang R, Chua D, Chu KM, Law WL, Law SY, Poon RT and Kwong A. Circulating microRNAs as specific biomarkers for breast cancer detection. PloS one. 2013; 8(1):e53141.
36. Chen W, Cai F, Zhang B, Barekati Z and Zhong XY. The level of circulating miRNA-10b and miRNA-373 in detecting lymph node metastasis of breast cancer: potential biomarkers. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013; 34(1):455-462.
37. Si H, Sun X, Chen Y, Cao Y, Chen S, Wang H and Hu C. Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. Journal of cancer research and clinical oncology. 2013; 139(2):223-229.
38. Cuk K, Zucknick M, Heil J, Madhavan D, Schott S, Turchinovich A, Arlt D, Rath M, Sohn C, Benner A, Junkermann H, Schneeweiss A and Burwinkel B. Circulating microRNAs in plasma as early detection markers for breast cancer. International journal of cancer Journal international du cancer. 2013; 132(7):1602-1612.
39. Sun Y, Wang M, Lin G, Sun S, Li X, Qi J and Li J. Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PloS one. 2012; 7(10):e47003.
40. Madhavan D, Zucknick M, Wallwiener M, Cuk K, Modugno C, Scharpff M, Schott S, Heil J, Turchinovich A, Yang R, Benner A, Riethdorf S, Trumpp A, Sohn C, Pantel K, Schneeweiss A, et al. Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2012; 18(21):5972-5982.
41. Cortez MA, Welsh JW and Calin GA. Circulating microRNAs as noninvasive biomarkers in breast cancer. Recent results in cancer research Fortschritte der Krebsforschung Progres dans les recherches sur le cancer. 2012; 195:151-161.
42. Wang H, Tan G, Dong L, Cheng L, Li K, Wang Z and Luo H. Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PloS one. 2012; 7(4):e34210.
43. Jung EJ, Santarpia L, Kim J, Esteva FJ, Moretti E, Buzdar AU, Di Leo A, Le XF, Bast RC, Jr., Park ST, Pusztai L and Calin GA. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 2012; 118(10):2603-2614.
44. van Schooneveld E, Wouters MC, Van der Auwera I, Peeters DJ, Wildiers H, Van Dam PA, Vergote I, Vermeulen PB, Dirix LY and Van Laere SJ. Expression profiling of cancerous and normal breast tissues identifies microRNAs that are differentially expressed in serum from patients with (metastatic) breast cancer and healthy volunteers. Breast cancer research: BCR. 2012; 14(1):R34.
45. Schwarzenbach H, Milde-Langosch K, Steinbach B, Muller V and Pantel K. Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast cancer research and treatment. 2012; 134(3):933-941.
46. Schrauder MG, Strick R, Schulz-Wendtland R, Strissel PL, Kahmann L, Loehberg CR, Lux MP, Jud SM, Hartmann A, Hein A, Bayer CM, Bani MR, Richter S, Adamietz BR, Wenkel E, Rauh C, et al. Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PloS one. 2012; 7(1):e29770.
47. Zhao R, Wu J, Jia W, Gong C, Yu F, Ren Z, Chen K, He J and Su F. Plasma miR-221 as a predictive biomarker for chemoresistance in breast cancer patients who previously received neoadjuvant chemotherapy. Onkologie. 2011; 34(12):675-680.
48. Yang M, Chen J, Su F, Yu B, Su F, Lin L, Liu Y, Huang JD and Song E. Microvesicles secreted by macrophages shuttle invasion-potentiating microRNAs into breast cancer cells. Molecular cancer. 2011; 10:117.
49. Sieuwerts AM, Mostert B, Bolt-de Vries J, Peeters D, de Jongh FE, Stouthard JM, Dirix LY, van Dam PA, Van Galen A, de Weerd V, Kraan J, van der Spoel P, Ramirez-Moreno R, van Deurzen CH, Smid M, Yu JX, et al. mRNA and microRNA expression profiles in circulating tumor cells and primary tumors of metastatic breast cancer patients. Clinical cancer research: an official journal of the American Association for Cancer Research. 2011; 17(11):3600-3618.
50. Asaga S, Kuo C, Nguyen T, Terpenning M, Giuliano AE and Hoon DS. Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clinical chemistry. 2011; 57(1):84-91.
51. Roth C, Rack B, Muller V, Janni W, Pantel K and Schwarzenbach H. Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast cancer research: BCR. 2010; 12(6):R90.
52. Ross JS. Measuring circulating miRNAs: the new "PSA" for Breast Cancer? The oncologist. 2010; 15(7):656.
53. Cheng HH, Yi HS, Kim Y, Kroh EM, Chien JW, Eaton KD, Goodman MT, Tait JF, Tewari M and Pritchard CC. Plasma processing conditions substantially influence circulating microRNA biomarker levels. PloS one. 2013; 8(6):e64795.
54. Chan M, Liaw CS, Ji SM, Tan HH, Wong CY, Thike AA, Tan PH, Ho GH and Lee AS. Identification of circulating microRNA signatures for breast cancer detection. Clinical cancer research: an official journal of the American Association for Cancer Research. 2013; 19(16):4477-4487.
55. Wang K, Yuan Y, Cho JH, McClarty S, Baxter D and Galas DJ. Comparing the MicroRNA spectrum between serum and plasma. PloS one. 2012; 7(7):e41561.
56. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, Miyaji MM, Tait JF and Tewari M. Blood cell origin of circulating microRNAs: a cautionary note for cancer biomarker studies. Cancer prevention research. 2012; 5(3):492-497.
57. Volinia S and Croce CM. Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 2013; 110(18):7413-7417.
58. Akanuma N, Hoshino I, Akutsu Y, Murakami K, Isozaki Y, Maruyama T, Yusup G, Qin W, Toyozumi T, Takahashi M, Suito H, Hu X, Sekino N and Matsubara H. MicroRNA-133a regulates the mRNAs of two invadopodia-related proteins, FSCN1 and MMP14, in esophageal cancer. British journal of cancer. 2014; 110(1):189-198.
59. Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, Chiyomaru T, Enokida H, Nakagawa M and Matsubara H. miR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. International journal of cancer Journal international du cancer. 2010; 127(12):2804-2814.
60. Nohata N, Hanazawa T, Enokida H and Seki N. microRNA-1/133a and microRNA-206/133b clusters: dysregulation and functional roles in human cancers. Oncotarget. 2012; 3(1):9-21.
61. Noren Hooten N, Fitzpatrick M, Wood WH, 3rd, De S, Ejiogu N, Zhang Y, Mattison JA, Becker KG, Zonderman AB and Evans MK. Age-related changes in microRNA levels in serum. Aging. 2013; 5(10):725-740.
62. Olivieri F, Rippo MR, Procopio AD and Fazioli F. Circulating inflamma-miRs in aging and age-related diseases. Frontiers in genetics. 2013; 4:121.
63. Ambrosone CB, Nesline MK and Davis W. Establishing a cancer center data bank and biorepository for multidisciplinary research. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 2006; 15(9):1575-1577.
64. Eisen MB, Spellman PT, Brown PO and Botstein D. Cluster analysis and display of genome-wide expression patterns. Proceedings of the National Academy of Sciences of the United States of America. 1998; 95(25):14863-14868.
65. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Statistical applications in genetics and molecular biology. 2004; 3:Article3.
66. Hochberg Y and Benjamini Y. More powerful procedures for multiple significance testing. Statistics in medicine. 1990; 9(7):811-818.